NEW YORK--(BUSINESS WIRE)--Among patients aged 65 and older with established coronary heart disease, Lipitor® (atorvastatin calcium) 80 mg significantly reduced the relative risk of a first cardiovascular event by 23 percent and provided significant reductions in the risk of subsequent second, third and fourth cardiovascular events over a period of five years compared to Lipitor 10 mg, according to data presented today at the 58th annual scientific sessions of the American College of Cardiology (ACC) in Orlando, FL. This post hoc sub-analysis was designed and completed following the Treating to New Targets (TNT) study.
